Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Antonio, Texas 78229


Phase II trial to study the effectiveness of irofulven in treating patients who have metastatic breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Study summary:

OBJECTIVES: I. Evaluate the response rate and time to treatment failure in patients with refractory metastatic adenocarcinoma of the breast treated with irofulven. II. Assess the qualitative and quantitative toxic effects of this drug in these patients. III. Determine the population pharmacokinetics and the pharmacokinetics-pharmacodynamic relationships of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive irofulven IV over 30 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.


DISEASE CHARACTERISTICS: - Histologically confirmed metastatic adenocarcinoma of the breast - Measurable disease outside previously irradiated area or occurred/progressed after completion of radiotherapy - Must have received 1 or 2 prior chemotherapy regimens for metastatic disease - More than 3 prior regimens allowed - No active brain metastases or meningeal breast cancer involvement PATIENT CHARACTERISTICS: Sex: - Male or female Performance status: - SWOG 0-2 Hematopoietic: - WBC at least 3,000/mm^3 - Platelet count at least 100,000/mm^3 - Absolute neutrophil count at least 1,500/mm^3 Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - SGOT or SGPT no greater than 3 times ULN (5 times ULN for liver metastases) Renal: - Creatinine no greater than 1.5 mg/dL OR - Creatinine clearance at least 60 mL/min Cardiovascular: - No history of myocardial infarction or unstable angina within the past 6 months - No uncontrolled congestive heart failure Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - Prior diagnosis of cancer allowed (must be off cancer therapy and have no evidence of disease) - No history of retinopathy and/or macular degeneration PRIOR CONCURRENT THERAPY: Chemotherapy: - No prior irofulven



Primary Contact:

Study Chair
Lisa Hammond, MD
University of Texas

Backup Contact:


Location Contact:

San Antonio, Texas 78229
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.